Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinomas, Resistance to Immunotherapy
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
Background： Hepatocellular carcinoma (HCC) stands as a formidable global health challenge. It ranks as the sixth most common malignant solid tumor worldwide and the third leading cause of cancer-related mortality.
- Conditions
- Hepatocellular Carcinomas, Resistance to Immunotherapy, Immunomodulation, Drug Repurposing
- Trial name
- NCT07324473
- Testing
- The triple-therapy strategy of Ivarmacitinib, Apatinib, and Camrelizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Hepatocellular Carcinoma, Glioblastoma
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer
- Trial name
- NCT05131763
- Testing
- NKG2D-based CAR T-cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin\&5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC). The program of FOLFOX-HAIC in HCC was performed for 1 day (HAIC 1d) or 2 days (HAIC 2d).
- Trial name
- NCT05476432
- Testing
- HAIC, FOLFOX 2d, FOLFOX 1d
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Colon Adenocarcinoma, Rectal Adenocarcinoma
Evaluating Novel Therapies in ctDNA Positive GI Cancers
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- MRD-GI (NCT05482516)
- Testing
- Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular…
- Trial name
- NCT03084380
- Testing
- Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Hepatocellular Carcinoma
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Positive micro vascular invasion in early stage hepatocellular carcinoma(HCC) leads to early recurrence after surgery. Adjuvant external radiotherapy will be applied in those patients to see if disease free survival and overall…
- Trial name
- NCT04891874
- Testing
- Stereotactic radiotherapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unresectable Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned.
- Trial name
- STOP-HCC (NCT01556490)
- Testing
- TheraSphere
- Where
- 94 sites in United States, Belgium and 9 more
- Volunteers
- 526 people
- Sponsor
- Boston Scientific Corporation
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Carcinoma, Hepatocellular
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Primary: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin Secondary: Safety and tolerability of this regimen in these…
- Trial name
- NCT00280618
- Testing
- Oxaliplatin
- Sponsor
- Sanofi
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.
- Trial name
- Wondercel-UWD3 (NCT06653023)
- Testing
- Universal CAR-T cells injection for treating HCC and NSCLC, MMF Immunosuppression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Hepatocellular Carcinoma
DKN-01 Inhibition in Advanced Liver Cancer
This clinical trial is a prospective, open label, single arm oncological phase I/II trial in patients with hepatocellular carcinoma and WNT signaling alterations.
- Trial name
- NCT03645980
- Testing
- DKN-01 300 mg, DKN-01 600 mg, Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Johannes Gutenberg University Mainz
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Liver Cancer
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
The purpose of this study is to explore the safety and tolerability of chidamide in combination with Sintilimab and bevacizumab in patients with advanced liver cancer, to determine the recommended dose for this combination…
- Trial name
- NCT06408623
- Testing
- chidamide combined with Sintilimab and bevacizumab
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Heart Failure, Copd
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus
- Trial name
- NCT04351880
- Testing
- Medically Tailored Meals
- Where
- 2 sites in United States
- Volunteers
- 650 people
- Sponsor
- Kaiser Permanente
Liver Transplantation, Hepatocellular Carcinoma
Prognosis Analysis of Elderly Donor Liver in Liver Transplantation
Based on the follow-up data of elderly donation after cardiac death(DCD) donor liver transplant recipients from the CLTR, a database and official website for national data gathering.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Survival
- Trial name
- NCT05355662
- Testing
- Age
- Volunteers
- 11,569 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Carcinoma, Hepatectomy
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
Although traditional open right hemihepatectomy is a mature technique, the incision is usually very large; Intraoperative bleeding may be excessive, and postoperative liver failure is also prone to occur.
- Conditions
- Hepatocellular Carcinoma, Hepatectomy, Laparoscopic Hepatectomy
- Trial name
- NCT06950827
- Testing
- laparoscopic right hemihepatectomy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- West China Hospital
Hepatic Malignant Neoplasm Primary Non-Resectable
Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
- Trial name
- NCT03266042
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Delcath Systems Inc.
Hepatocellular Carcinoma
A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and the third most frequent cause of death of cancer.Although with the development of medical science, more and more patients diagnose HCC at early stage, a…
- Trial name
- NCT02061956
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.